Skip to main content

Table 1 General characteristics of the population included in the study (n = 553)

From: Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients

 

N. patients (%)

Non-STR (n = 457)

STR (n = 96)

P value

Baseline calendar year

    

  19992003

187 (33.8)

187 (40.9)

/

 

  20042007

181 (32.7)

181 (39.6)

/

 

   2008-2012

185 (33.5)

89 (48.1)

96 (100.0)

 

Age, years a

39 (33–45)

38 (33–45)

42 (32–47)

0.06

Male gender

391 (70.7)

324 (70.9)

67 (69.8)

0.83

Non-Italian nationality

130 (23.0)

103 (23.4)

27 (28.1)

0.24

Injecting drug use (as risk factor)

93 (11.4)

57 (12.5)

6 (6.3)

0.08

CDC class C

130 (23.5)

109 (23.9)

21 (21.9)

0.68

Years from HIV diagnosis a

2.6 (0.7-7.4)

2.5 (0.5-7.4)

3.0 (1.4-7.6)

0.09

Naïve

283 (51.2)

248 (54.3)

35 (36.5)

0.002

Number of treatment lines at EFV start a,c

2 (2–3)

3 (2–3)

2 (2–3)

0.17

Baseline Viral Load, log copies/mL a,b

4.8 (4.6-5.2)

4.8 (4.6-5.3)

4.8 (4.1-5.3)

0.35

Nadir CD4 cells count, cells/μL a

196 (93–262)

180 (91–248)

246 (121–326)

0.1

Baseline CD4 cells count, cells/μL a

300 (207–437)

275 (185–433)

430 (322–573)

0.55

Co-administered NRTIs:

    

  TDF + FTC/3TC

315 (57.0)

219 (47.9)

96 (100.0)

 

  ABC + 3TC

21 (3.8)

21 (4.6)

/

 

  AZT + 3TC

130 (23.5)

130 (28.5)

/

 

  Other

87 (15.7)

87 (19.0)

/

 
  1. Notes: values are expressed as number (percentage), except for amedian (interquartile range); bnaïve patients; cexperienced patients. Bold values are statistically significant p values.
  2. Abbreviations: BID twice daily, OD once daily, STR single tablet regimens, EFV efavirenz, NRTIs nucleoside reverse transcriptase inhibitors, TDF tenofovir, FTC emtricitabine, 3TC lamivudine, ABC abacavir, AZT zidovudine: D4T, stavudine.